COLQ
Acetylcholinesterase collagenic tail peptide
Also known as: COLQ_HUMAN, EAD
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9Y215
- Gene
- COLQ
- Ensembl
- ENSG00000206561
- Chromosome
- 3
- Canonical length
- 455 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Plasma membrane,Cell Junctions
- Secretome location
- Secreted to blood
- Quaternary structure
- Homotrimer
OverviewNCBI Gene
This gene encodes the subunit of a collagen-like molecule associated with acetylcholinesterase in skeletal muscle. Each molecule is composed of three identical subunits. Each subunit contains a proline-rich attachment domain (PRAD) that binds an acetylcholinesterase tetramer to anchor the catalytic subunit of the enzyme to the basal lamina. Mutations in this gene are associated with endplate acetylcholinesterase deficiency. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
455 residues, UniProt reviewed canonical sequence.
>Q9Y215|COLQ
1 MVVLNPMTLG IYLQLFFLSI VSQPTFINSV LPISAALPSL DQKKRGGHKA CCLLTPPPPP
61 LFPPPFFRGG RSPLLSPDMK NLMLELETSQ SPCMQGSLGS PGPPGPQGPP GLPGKTGPKG
121 EKGELGRPGR KGRPGPPGVP GMPGPIGWPG PEGPRGEKGD LGMMGLPGSR GPMGSKGYPG
181 SRGEKGSRGE KGDLGPKGEK GFPGFPGMLG QKGEMGPKGE PGIAGHRGPT GRPGKRGKQG
241 QKGDSGVMGP PGKPGPSGQP GRPGPPGPPP AGQLIMGPKG ERGFPGPPGR CLCGPTMNVN
301 NPSYGESVYG PSSPRVPVIF VVNNQEELER LNTQNAIAFR RDQRSLYFKD SLGWLPIQLT
361 PFYPVDYTAD QHGTCGDGLL QPGEECDDGN SDVGDDCIRC HRAYCGDGHR HEGVEDCDGS
421 DFGYLTCETY LPGSYGDLQC TQYCYIDSTP CRYFTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against COLQ can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.65
- Highest tissue expression
- 17 nTPM
Expression across tissuesHPA
Tissue
- heart muscle: 17 nTPM
- choroid plexus: 14 nTPM
- skeletal muscle: 8.6 nTPM
- fallopian tube: 8.3 nTPM
- tongue: 4.8 nTPM
- lymph node: 3.6 nTPM
Single-cell type
- myonuclei: 212 nCPM
- choroid plexus epithelial cells: 166 nCPM
- ependymal cells: 138 nCPM
- nk-cells: 87 nCPM
- brain inhibitory neurons: 56 nCPM
- brain excitatory neurons: 51 nCPM
Immune cell
- MAIT T-cell: 61 nTPM
- gdT-cell: 10 nTPM
- memory CD8 T-cell: 7.4 nTPM
- memory CD4 T-cell: 5.3 nTPM
- total PBMC: 3.5 nTPM
- NK-cell: 1.8 nTPM
Brain region
- choroid plexus: 27 nTPM
- medulla oblongata: 12 nTPM
- cerebral cortex: 11 nTPM
- cerebellum: 9.5 nTPM
- hippocampal formation: 9.3 nTPM
- midbrain: 8.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about COLQ.
Disease | AllUniProt
Conditions COLQ is implicated in, by any mechanism.
- Myasthenic syndrome, congenital, 5 (CMS5) MIM:603034
Disease | GeneticClinVar
120 pathogenic / likely-pathogenic of 664 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Congenital myasthenic syndrome 5
- Congenital myasthenic syndrome
- Abnormality of the musculature
- Synaptic congenital myasthenic syndromes
- Slow-Channel Congenital Myasthenia Syndrome
ReferencesPubMed · IEDB
Publications for COLQ from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis.
2025 · J Neuroimmunol · RCR 1.8 · 5 citations - Collagen Q--a potential target for autoantibodies in myasthenia gravis.
2015 · J Neurol Sci · RCR 1.5 · 36 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.1
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.22
- DepMap mean gene effect
- 0.13
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- acetylcholine catabolic process in synaptic cleft
- establishment of protein localization to membrane
- negative regulation of synaptic transmission, cholinergic
- protein localization to synapse
- regulation of synaptic assembly at neuromuscular junction
- skeletal muscle acetylcholine-gated channel clustering
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of COLQ in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads COLQ as an antibody target. Whether an autoantibody or antibody against COLQ could matter depends on whether native COLQ is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
COLQ is annotated at the cell surface, where native COLQ is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label COLQ as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...